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Diminished response of ovarian cAMP to luteinizing hormone
in experimental uremia
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Department of Internal Medicine, Division of Nephrology, University of Heidelberg, Heidelberg, Germany
Diminished response of ovarian cAMP to luteinizing hormone in
experimental uremia. In prepuberal female rats with acute bilateral
nephrectomy or chronic subtotal nephrectomy, the increase of ovarian
cAMP concentration in response to submaximal doses of luteinizing
hormone (LH 10 rg) and human chorionic gonadotropine (hCG 2.5 IU)
was diminished (CO + 2.5 IU hCG 488 49 pmoles cAMP/mg protein;
MX + 2.5 IU hCG 366 56, P < 0.05). The cAMP response to follicle
stimulating hormone (FSH) was unchanged. The abnormality was
found both after administration of LH in vivo and incubation of ovaries
with LH in vitro. Similarly, plasma estradiol concentrations in response
to submaximal hCG stimulation were diminished. Basal cAMP concen-
trations and cAMP concentrations after maximal stimulation were
unchanged. The defect was observed both in ovaries of untreated
prepuberal rats, of pregnant mare serum (PMS)-treated rats (follicular
phase) and PMS/hCG-treated rats (luteal phase). Diminished ovarian
cAMP response to LH was observed both in parathyroid intact and in
parathyroidectomized rats. Administration of 1 ,25(OH)2D2 in physio-
logical doses (60 ng/kg) to acutely uremic rats restored diminished
ovarian cAMP response to submaximal LH stimulation irrespective of
parathyroid status. The effect of I ,25(OH)2D3 could not be reproduced
by hypercalcemia resulting from intraperitoneal calcium injection. In
vivo administration of indomethacin further diminished ovarian cAMP
response in uremic animals and had no effect in control animals.
Incubation of ovaries with POE1 and PGE2 increased basal and
stimulated cAMP concentrations and abolished the difference between
control and uremic animals. The diminished response of ovarian cAMP
content to submaximal doses of hCG was not corrected by bromocrip-
tine (1 mg/kg) despite normalization of hyperprolactinemia. The present
study shows diminished ovarian cAMP and plasma estradiol response
to LH in experimental uremia. It documents a role of I ,25(OH)2D3 and
prostaglandins in the genesis of this abnormality.
Diminution de Ia reponse du cAMP ovarien a I'hormone Iutéinisante
dans I'urémie expérimentale. Chez des rates prépuberes ayant one
néphrectomie bilatérale aigue ou une néphrectomie subtotale chro-
nique, l'augmentation de Ia concentration ovarienne de cAMP en
réponse a des quantités sous-maximales d'hormone lutéinisante (LH 10
g) et de gonadotrophine chorionique humaine (hCG 2,5 IU) était
diminuée (CO + 2,5 IU hCG 488 49 pmoles cAMP/mg de protéines;
NX + 2,5 IU hCG 366 56, P < 0,05). La réponse do cAMP a
l'hormone folliculinique (FSH) était inchangee. Cette anomalie a été
trouvée aussi bien après administration de LH in vivo qu'après incuba-
tion des ovaires avec de La LH in vitro. De même, les concentrations
plasmatiques d'estradiol en réponse a une stimulation sous-maximale
par l'hCG étaient diminuées. Les concentrations basales de cAMP et
les concentrations de cAMP après stimulation maximale étaient inchan-
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gées. Ce trouble a été observe dans les ovaires de rates prépubères non
traitCes, de rates traitCes par du serum dejument gravide (PMS) (phase
folliculaire) et de rates traitées par PMS/hCG (phase lutCale). La
diminution de Ia reponse ovarienne du cAMP a Ia LI-I a été observée
chez des rates aux parathyroIdes intactes, et chez des rates parathyroi-
dectomisées. L'administration de I ,25(OH)D3 a doses physiologiques
(60 ng/kg) a des rates rendues urCmiques de facon aigue a restauré La
réponse diminuée du cAMP ovarien a une stimulation sous-maximale
de LH, quel que soit l'état parathyroidien. L'effet de Ia I ,25(OH)D n'a
Pu être reproduit par une hypercalcémie obtenue par injection intrapéri-
tonéale de calcium. In vivo, I'administration d'Indométhacine a encore
diminuC La réponse du cAMP ovarien chez les animaux urCmiques, mais
na pas eu d'effet chez les animaux contrOles. L'incubation des ovaires
avec de Ia PGE1 et de Ia POE2 a augmenté Les concentrations de cAMP
basales et aprCs stimulation, et a aboli Ia difference entre les animaux
contrôles et uremiques. La diminution de rbponse du contenu ovarien
en cAMP a des doses sous-maximales d'hCG n'a pas Cté corrigée par Ia
bromocriptine (1 mg/kg) malgré Ia normalisation de l'hyperprolactinC-
mie. Cette étude rnontre une diminution de La rCponse du cAMP ovarien
et de I'oestradiol plasmatique a La LH lors de l'urCmie expérimentale. Il
suggere un rOle de Ia I ,25(OH)2D3 et des prostaglandines dans Ia génese
de cette anomalie.
Menstrual abnormalities, infertility, and diminished libido are
common in uremic women [1—4]. The disturbances of female
sexual function in uremia involve different levels of the normal
hormonal feedback systems. A disturbance at the hypothalam-
ic-hypophyseal level was established clearly by the investiga-
tions of Lim et al [3] and Swamy, Woolf, and Cestero [4]. In
addition, a disturbance at the gonadal level has been postulated
by several investigators. This postulate is based on the observa-
tion that luteinizing hormone (LH) levels, and less commonly
follicle stimulating hormone (FSH) levels, are elevated in many
uremic patients despite low levels of circulating sexual steroids.
The phenomenon has been established clearly in uremic men [5,
6]. In uremic women, this constellation is more difficult to
demonstrate because of the cyclic changes of hormone levels.
In some patients, at least, such a constellation has been
demonstrated by Lim et a! [3] and Swamy, Woolf, and Cestero
[41. High gonadotropin levels despite low or normal estrogen
levels point to the presence of hypergonadotropic hypogona-
dism, that is, end-organ resistance.
The effect of LH on the ovary involves activation of hor-
mone-sensitive adenylate cycLase and a series of events culmi-
nating in increased sexual steroid synthesis [7]. This sequence
is importantly influenced by prostaglandins [8]. ProstagLandin
metabolism is disturbed in uremia [9] and in other hormonal
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systems evidence for prostaglandin dependent end-organ resist-
ance in uremia was found in previous studies [10].
Hyperprolactinemia is commonly found in uremic individuals
[3—61. The role of hyperprolactinemia, if any, in the genesis of
ovarian resistance to LH has not been defined.
Furthermore, Massry et a! [111 observed improvement of
disturbed sexual function and an increase of testosterone in
uremic man after administration of 1,25(OH)7D3. It was sug-
gested that the effect of 1 ,25(OH)7D3 resulted Crom suppression
of parathyroid hormone (PTH), but a direct action of
I ,25(OH)D3 on the gonad has not been excluded.
It was the purpose of this investigation to study ovarian
cAMP concentrations and circulating estradiol levels in re-
sponse to gonadotropins. Furthermore, the effects of pharma-
cological interventions with prostaglandins, dopaminergic ago-
nists, and vitamin D metabolites were studied. The results can
be explained by the presence of end-organ resistance to gonad-
otropins in experimental uremia.
Methods
Animals. Prepuberal female Wistar rats with an initial body
weight of 35 g (age, 20 to 25 days) were used for the experiments
(Firma Ivanovas, Kisslegg, Allgau, Germany). The animals had
free access to normal chow diet (Altromin C 1047) and distilled
water. They were adapted for 3 days to housing conditions at
constant room temperature (25° C), constant humidity (70%),
and exposure to a 12-hr light on—l2-hr light off cycle.
Experimental protocol
All experimental groups comprised at least seven animals and
all experiments were done at least in duplicate.
Acute uremia was induced by bilateral nephrectomy in ether
anesthesia 24 hr prior to the experiment. Water was withheld
thereafter. Control animals were sham-operated by incision of
the dorsal musculature and decapsulation of the kidney.
Chronic uremia was induced by subtotal (9/10) nephrectomy:
One kidney was resected subtotally and the opposite kidney
removed. A second resection was carried out after 7 days. The
animals were sacrificed 20 days later. At that time, serum urea
was 201 9.8 mg/dl in nephrectomized rats (NX) and 36.2 2.4
mg/dl in controls.
Follicle transformation and luteinization. In one series, fol-
licular transformation and luteinization of the ovaries were
achieved with the experimental protocol of Mason, Schaffer,
and Toomey [12]: Female rats were given 75 U/PMS (pregnant
mare serum; IJCB Chemicals Bruxelles, Belgium), dissolved in
saline, 58 hr prior to the end of the experiment to achieve
follicular transformation of the ovaries; luteinization of the
ovary was achieved by administration of PMS (75 U) 120 hr,
and 33 IU hCG (human chorionic gonadotropin, Primogonyl®,
Firma Shering, Berlin, Germany) s.c. 72 hr prior to the end of
the experiment. For this and the following experiments, animals
were made acutely uremic (see Acute uremia).
Thyroparathyroidectomy (TPTX). In one series of experi-
ments, animals were subjected to surgical TPTX immediately
prior to acute bilateral nephrectomy. Animals were used for the
study if serum calcium decreased by more than 1 .5 mmoles/
liter. In another series of experiments, 1,25(OH)2 vitamin D3 (2
or 4 ng/animal as indicated in the tables) was administered at the
time of surgery and 2 hr before the experiment by intraperitone-
al injection. For each injection, the dose of l,25(OH)2D3 (Firma
Hoffmann La Roche, Basel, Switzerland) was dissolved in 0.3
ml Cremophore® (Firma Imhoff and Stahl, Mannheim, Germa-
ny). Control animals received solvent injection.
In a further series of experiments, acutely uremic animals
were given either saline or calcium gluconate (4 x 100 mg
Ca) by intraperitoneal injection 48, 36, 24, and 12 hr prior to
the end of the experiment.
Indomethacin. In another series, indomethacin (Firma Sig-
ma, München, Germany) dissolved in saline, was administered
in a dose of 1 mg/kg 24, 12 and 2 hr prior to the end of the
experiment. Control animals received saline intraperitoneally.
Bromocriptine. In yet another series of experiments, animals
with acute bilateral nephrectomy received 1 mg/kg bromocrip-
tine (Firma Sandoz, Base!, Switzerland), dissolved in tartaric
acid and 60% alcohol (1: 1 v/v) and diluted with isotonic saline,
by subcutaneous injection 24 and 2 hr prior to the end of the
experiment.
Stimulation with gonadotropins. In all the above groups, the
ovaries were stimulated with gonadotropins, that is, equine LH
or porcine FSH (Firma Paesel, Frankfurt, Germany) or hCG in
the specified dose 15 mm prior to the end of the experiment by
intravenous injection into the jugular vein under ether anesthe-
sia. Control animals received solvent injection. The doses of
LH or FSH refer to Armour standard. hCG (Primogonyl, Firma
Schering, Berlin, Germany) was calibrated against the second
international standard for hCG; 1 IU 1.279 g of the second
international standard substance.
Preparation of ovaries. At the end of the experiments,
animals were anesthesized with ether and laparatomized. For
the in vivo studies, the ovaries then were removed quickly and
immediately deproteinized in 6% ice cold trichloracetic acid
(TCA) for analysis. For in vitro incubation studies, both ovaries
were removed from the animals in ether anesthesia, tissue was
cleaned in cold saline, and then whole ovaries were transferred
to Krebs Ringer bicarbonate (pH 7.4; incubation temperature
37° C) and incubated in a shaking water bath at 60 cycles/mm in
an atmosphere with 5% CO2 to 95% 02. The incubation medium
contained I mmole/liter Ca, 10 mmoles/liter glucose, and 5
mmoles/liter theophylline. The final incubation volume was 1
ml in all experiments. The tissues were incubated for 20 mm.
Reagents or solvent were added as indicated in Tables 2 and 3.
Prostaglandin E1 and E2 (Firma Serva Feinbiochemica, Heidel-
berg, Germany) were used. The incubation was terminated by
addition of ice cold 0.5 ml 6% TCA.
Analytical procedures
After homogenization (Sorvall Omnimixer) of the deprotein-
ized tissue, the material was centrifuged (X4000 g) for 10 mm at
room temperature. The supernatant was extracted with water
saturated ether. The protein content of the pellet was measured
in the manner of Lowry et al [13]. For cyclic 35' adenosine
monophosphate (cAMP) measurements, the samples were acet-
ylated. It could be shown in preliminary experiments that
purification of supernatant with resine (Dowex XW 5; 200 to
400 mesh; hydrogen form) was unnecessary. With the antibody
used (NEN Company, Dreieichenhain, Germany) no detectable
unspecific binding was observed (no difference between puri-
fied and unpurified samples). Recovery of exogeneous cAMP
with resine purification was 80%, and for the ether extracted
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Table 1. Effect of FSH and LH on ovarian cAMP (pmole/mg protein) of uremic rats in vivoa
Dose FSH Dose LI-I
0 1 5 50 500 0 5 50 100 500
Control 25 3.1 48 6.0 807 115 1040 152 1293 132 (N = 8) — 70 5.3 102 13 168 22 652 82
(N =7)
Uremia 28 2.2 55 4.1 703 102 880 148 1264 192 (N = 8) — 61 5.4 71 lOb 86 7•9h 650 101
(N =7)
____ _____________
Measurement was made 15 mm after administration of FSH or LH intravenously. Values are given as mean SEM.
-
Numerals denote a significant difference between uremic and control animals (P < 0.05).
TCA supernatant without resine purification, recovery was
100%. Replicate measurements of the same TCA extract varied
by no more than 5%. The antibody for cAMP used was double
labeled and its affinity was higher by a factor of 106 for cAMP as
compared with other nucleotides (for example, cGMP, ATP,
ADP, AMP). For radioimmunoassay of cAMP, the procedure
of Steiner et a! 14j was used.
Plasma estradiol levels were measured with a radio-
immunoassay (RIA) 15j (courtesy of Professor Runnebaum,
Heidelberg). The test kit of Eiria (Wurenlingen, Switzerland)
was used. Sensitivity was 0.5 pg/tube and cross-reactivity with
estrone, estriol (0.02), progesterone, testosterone, and andros-
tandiol (0.001) was negligible. Plasma prolactin was measured
with a rat-specific antibody by RIA (courtesy Professor Del
Pozo, Sandoz Company, Base!, Switzerland). Serum urea was
measured enzymatically (Firma Boehringer, Mannheim, Ger-
many). Serum calcium was measured by atomic absorption
spectrophotometry (Perkin Elmer Company, Frankfurt,
Germany).
Statistics
Animals were allotted at random to the experimental group
with the use of random numbers. All data are given as mean
SEM. Differences between groups were tested nonparametrical-
ly with Wilcoxon's test for random samples or with two
factorial analysis of variance (courtesy Professor Scheuerlen,
Department Biostatistics, University of Heidelberg).
Results
Ovarian cAMP response and plasma estradiol to in vitro and
in vivo administration of LH, FSH and hCG in acute uremia.
As shown in Figure 1 A and B, the dose response curve for LH
in vitro, but not FSH in vitro, was abnormal for ovaries of
uremic animals. An abnormal dose response curve could also
be shown for hCG in vitro (data not given).
As shown in Table 1, basal ovarian cAMP concentrations and
ovarian cAMP concentrations with the highest dose of LH (500
tg) were not different in uremic animals and sham-operated
control animals in vivo. In contrast, the cAMP concentration
response to submaximal doses of LH (100 tg) was attenuated
markedly.
This was paralleled by a less pronounced increase of plasma
estradiol concentrations 30 mm after 2.5 IU hCG injection
(basal levels undetectable in controls and uremia; after stimula-
tion: 11.6 1.4 pg/mI in controls (N = 10); 7.05 1.2 pg/ml in
uremia (N = 10); difference P < 0.05).
In contrast, no difference of dose response relationship of
ovarian cAMP between control animals and uremic animals was
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Fig. 1. Dose response curve of ovarian cAMP
concentralion after incubation (volume / ml)
with rising concentrations of LH (A) and FSH
(B). At each dose, ovaries (4.1 0.3 mg) of nine
sham-operated control and ovaries (4.0 0.4
mg) of nine uremic animals were examined.
Values are given as mean SEM. Differences
between control and uremic animals were sig-
nificant (analysis of variance) for LH but not for
FSH.
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Fig. 4. Ovarian cAMP content after 2.5 IU hCG inovaries qfprepuberal
rats, PMS-pretreated rats (follicular phase) and PMS/hCG-pretreated
rats (luteal phase) with acute uremia. The difference between control
and uremic III animals was significant (P < 0.05, asterisk) in the
prepuberal and follicular phases. The difference in the luteal phase was
not significant. The wet weights of the ovaries were as follows:
prepuberal CO, 3.8 0.2 mg; NX, 3.8 0.4; follicular phase, CO, 17
1.4; NX, 10.8 1.9; P 0.05; luteal phase, CO, 96 13.6; NX, 99 8.4.
In each group eight animals were examined.
of the cAMP concentration response to hCG in the ovaries of
uremic animals could be established (Fig. 3).
Ovarian cAMP response to in vivo administration of hCG in
chronic uremia. Diminished cAMP response to submaximal
hCG stimulation was observed not only in acutely (24 hr)
binephrectomized rats but also in subtotally nephrectomized
rats with uremia of 20 days' duration (no difference of basal
cAMP and cAMP after maximal stimulation with 50 IU hCG;
with 10 IU: NX, 830 95 pmoles cAMP/mg protein; CO, 1450
63 pmoles cAMP/mg protein; N = 7 per group; difference P <
0.01).
cAMP response to hCG in ovaries of prepuberal, PMS
pretreated (follicular phase), and PMS-hCG-pretreated (luteal
phase) rats with acute uremia. As shown in Figure 4, a similarly
attenuated cAMP response to hCG in vivo was observed in
ovaries of nonpretreated prepuberal rats and PMS-pretreated
rats with ovaries in the follicular phase. For PMS-hCG-pretreat-
ed rats, that is, ovaries with luteal transformation, a similar
trend was observed but the difference was statistically not
significant.
Effects of modification of calcium metabolism on ovarian
cAMP response to hCG (thyroparathyroidectomnv and adminis-
tration of 1,25(OH)7D3). TPTX prior to NX did not affect either
basal cAMP or cAMP response to hCG in vivo as shown in
Figure 5. Acute intravenous injection of 20 IU 1,34 bPTH
(Beckman Company, Fullerton, California) 120 mm prior to the
end of the experiment was without effect on basal or submaxi-
mally stimulated cAMP in sham-operated control animals and
uremic animals (Table 2). Similarly, no effect of co-incubation
with PTH (0.1, 1 .0, or 10 IU/ml) in vitro on ovarian cAMP was
noted. Table 2 gives results for 10 IU PTH/ml.
Pretreatment of uremic animals with 1 ,25(OH)7 vitamin D3 (2
ng/animal 24 and 2 hr prior to the end of the experiment)
o—o Control
Uremia
0 0.1
600-
0
0,
E
400-0
E
0.
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200
0J
1 10 100
hCG, IU
Fig. 2. Dose response curve of ovarian cAMP content 15 mm after
administration of hCG. At each dose, seven sham-operated control and
seven uremic animals were examined. Values are given as mean SEM.
Difference between uremic and control animals was significant (P <
0.01).
300
2001
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o
J/
-—- Uremia
0
0 30 60 90
Time after hCG stimulation, mm
Fig. 3. Time course of ovarian cAMP content following stimulation with
a submaximal (2.5 IU) dose of /ICG. At each point in time, seven sham-
operated control and seven uremic animals were examined. Values are
given as mean SEM. The difference between control and uremic
animals was significant (P < 0.05).
observed after injection of FSH (Table 1). As shown in Figure
2, the dose response relationship for hCG was similarly abnor-
mal as that for LH. Because hCG has almost exclusively LH
activity and is more easily available, all subsequent in vivo
experiments were carried out with hCG. In addition to a
disturbed dose response relationship, an abnormal time course
*11
Lineal
phase
300-
H
Prepuoerau
phase
Follicuiar
phase
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Fig. 5. The effect of in vivo administration qf
physiological doses of 1,25(OH)2 vitamin D (2
x 2 ng/animal) on ovarian cAMP response to
2.5 JU hCG administration in parathyroid in-
tact (non-TPTX) and thyroparathyroidecto-
mized (TPTX) animals. In each non-TPTX-
group, seven animals and in each TPTX group,
13 animals were examined. Values are given as
mean SEM. Significant difference (P < 0.05,
asterisk) between control and uremic 1111
animals was found in solvent-treated, but not in
I ,25(OH)D3-treated animals irrespective of
parathyroid status (in non-TPTX as well as in
TPTX animals).
Table 2. Effect of PTH on basal and stimulated ovarian cAMP (pmole/mg protein) in vivo and in vitro
Basal hCG (or LH) stimulation
Solvent PTH Solvent PTH
In vivob
Control
(N = 8)
Uremia
(N =8)
In vitroc
Control
(N = 6)
Uremia
(N =6)
30 4.6 28 4.7 488 49 456 31
28 3.4 27 5.1 366 56d 286 44
12 1.6 14 1.3 244 10 264 15
IS 1.6 15 1.0 198 14d 196 6.Sd
Values are given as mean SEM.
b Measurements were taken in vivo IS mm after administration of 2.5 IU hCG and 20 IU PTH.
Measurements were taken in vitro 20 mm after incubation with 10 sg LH/ml and 10 IU PTH/ml.
Value denotes a significant difference between uremic and control animals (P < 0.05).
completely normalized ovarian cAMP concentration in re-
sponse to submaximal doses of hCG in acutely uremic animals
irrespective of parathyroid status. No effect was observed in
control animals (Fig. 5). In parathyroid intact control or uremic
animals, the above dose of 1 ,25(OH)2D3 did not significantly
change serum calcium concentration. Furthermore, injection of
calcium (4 X 100 mg i.p.) resulted in significant elevation of
serum calcium (CO without calcium injection, 2.1 0.21
mmoles/liter; CO with calcium, 7.5 6.8). Such hypercalcemia
resulted in marked diminution of the ovarian cAMP content
after submaximal hCG stimulation (276 41 pmoles/mg protein
after 5 IU hCG 15 mm prior to the end of the experiment in
hypercalcemic animals; 851 55 pmoles/mg protein in normo-
calcemic animals).
Effect of indomethacin in vivo and prostaglandins in vitro on
ovarian cAMP response to LH in acutely uremic rats. Pretreat-
ment with indomethacin (1 mg/kg 48, 24, and 2 hr prior to the
end of the experiment) further diminished ovarian cAMP re-
sponse to submaximal stimulation of hCG (2.5 U) in uremia
[NX without INDO 150 11 pmoles/mg protein; NX with
INDO 84 8.7 pmoles/mg proteini but had no effect in sham-
operated control animals controls without INDO 176 12
pmoles/mg protein; controls with INDO 175 15 pmoles/mg
proteini. The effect of indomethacin in uremia was significant
(P < 0.01).
In preliminary experiments, ovarian cAMP after LH (10
tg/ml) stimulation in vitro was unaffected by 0.1 .rg PGE1/ml;
the difference between control and uremic animals was abol-
ished completely by 1 rg PGE1/ml (1.18-fold stimulation of
cAMP content), 10 ug PGE1/ml (2.28-fold) and 100 .rg PGE1/ml
(7.6-fold). At 100 rg PGE1/ml, LH-stimulated ovarian cAMP
was 1639 92 pmoles cAMP/mg protein in uremic and 1441
201 pmoles cAMP/mg protein in control animals. For the
experiments shown in Table 3, an intermediate dose of PGE1
was chosen. The table documents the marked increase of basal
and submaximal stimulated ovarian cAMP when ovaries of
control or uremic animals are incubated with either PGE1 and
PGE2. The difference between control and uremic animals was
abolished by either prostaglandin.
Effects of bromocriptine on cAMP response to hCG in vivo of
acutely uremic rats. Prepuberal animals were given bromocrip-
tine (1 mg/kg) 24 and 2 hr prior to the end of the experiment.
Such pretreatment with bromocriptine lowered prolactin levels
both in CO and in NX (Table 4). Neither basal cAMP nor
submaximally stimulated cAMP was affected significantly by
pretreatment with bromocriptine.
I
TPTX
1,25 IOH),D3
*
L_______
Non-i r I A
solvents
Non-irpA TPTX
1,25 (OH)2D3 solvents
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Table 3. Effect of prostaglandin E1 and E2 on basal and LH-stimulated ovarian cAMP (pmole/mg protein) in vitroa
LH PGE1 PGE2 PGE1 + LH PGE2 + LH
Control 156 16 648 125 654 73 771 82 704 76
(N =8)
Uremia 100 95 779 88 778 55 851 88 836 75
(N =8)
Measurement was taken 20 mm after incubatiorL with 10 g LH/ml or 25 g PGE1 or PGE2 per milliliter. Values are given as mean SEM.
' Value denotes a significant difference between uremic and control animals (P < 0.01).
Table 4. Effect of bromocriptine on prolactin levels and on hCG stimulated ovarian cAMP (pmole/mg protein) in uremiaa
hCG hCG +
Solvents Bromocriptine Stimulation Bromocriptine
Prolactin concentration, ng/ml
Control
(N =8)
Uremia
(N =8)
cAMP concentration, pmole/mg prot
Control
(N =8)
Uremia
(N =8)
25 2.8 33 4.1 457 71 359 37
33 4.1 35 9.0 232 30b 198 24
a Administration of bromocriptine (1 mg/kg) 24 and 2 hr prior to the end of the experiment. Measurement was taken 15 mm after 2.5 IU hCG or
solvents. Values are given as mean SEM.
b Value denotes a significant difference between uremic and control animals (P < 0.05).
Discussion
The genesis of hypogonadism in renal failure is multifactorial
and involves several levels of hormonal regulation (hypothala-
mus, gonads, end-organs). This study addressed the gonadal
abnormalities in hypogonadism of uremia. The study confirms
clinical observations of gonadal resistance to gonadotropins
(hypergonadotropic hypogonadism) in the female sex [3, 4]. In
renal insufficiency, end-organ resistance to hormonal action is
not unique for gonadotropins, since resistance to PTH [16],
insulin [171, and other hormones [10] has also been
demonstrated.
This study shows an inappropriate ovarian cAMP response to
LH but not to FSH. The results, therefore, relate to inadequate
gonadal steroidogenesis in uremia but do not bear on defective
generative function. A similar discrepancy between LH and
FSH responsiveness has been described for the testis of uremic
animals [181. It is of note that in uremic man, LH was found
consistently to be elevated [5, 6, 19—201, whereas in most
reports FSH levels were found to be normal but inappropriate
to the prevailing defect of spermatogenesis [23]. In women,
analysis is complicated by cyclic changes of gonadotropins but
at least in some premenopausal women, high LH levels were
observed [3, 4]. Non-cyclic increase of LH secretion may also
account for the syndrome of polycystic ovaries which has been
described repeatedly in uremic women [24].
In this study, the finding of unchanged basal cAMP concen-
tration is surprising in the face of the known elevation of
gonadotropins in acute experimental uremia [25]. However, the
sensitivity of our method may have been inadequate to detect
minor differences. Furthermore, compartmentation of ovarian
cAMP may have masked an increase of cAMP in one critical
compartment. Finally, because of the lability of cAMP, some
decay of cAMP prior to deproteinization cannot be reliably
excluded, but unchanged basal cAMP was also found after in
vitro incubation in the presence of theophylline.
The inadequate increase of ovarian cAMP in response to
submaximal stimulation with LH (or for logistic reasons, with
the more readily accessible substitute hCG for in vivo studies)
could be due to diminished generation of cAMP or due to its
increased catabolism. One argument against increased catabo-
lism via phosphodiesterase is the unchanged response to maxi-
mal stimulation. Furthermore, direct measurement of low Km
and high Km phosphodiesterase after Thompson and Appleman
[261 failed to reveal a difference between the ovaries of control
animals and uremic animals (data not given). Because of cell
heterogeneity and compartmentation of phosphodiesterase ac-
tivities, this finding is not absolutely conclusive. However, a
submaximal increase of cAMP concentration to LH was also
observed in vitro both in the presence and in the absence of 5
mmoles/liter theophylline.
Diminished cAMP generation in response to submaximal
hormonal stimulation with LH could be due to diminished
number and/or affinity of receptors, defective coupling or
altered adenylate cyclase activity. In the testis of uremic rats,
unchanged LH binding was observed [16] and in preliminary
studies, no diminution of LH binding was observed in ovaries of
uremic rats (data not given). The other possibilities were not
examined directly.
Diminished ovarian cAMP is not necessarily indicative of
disturbed ovarian function. In the gonad, only a small fraction
12.3 2.9
21.5 3.2k
8.30 3.0
7.23 2.9
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of total cAMP is required for maximal activation of gonadal
steroidogenesis [27], and this can be explained by the spare
receptor hypothesis. In this study, however, diminished cAMP
response to LH in ovaries of uremic rats was paralleled
presumably by similarly diminished steroidogenesis, because
we also found diminished LH stimulated plasma estradiol
concentrations.
A number of factors have been incriminated for disturbed
gonadal function in uremia, for example, hyperparathyroidism
[9] or disturbed calcium metabolism, hyperprolactinemia [28],
cellular Zn-deficiency [29], and so forth. Experiments were
designed to elucidate the role of some of these factors in the
genesis of ovarian resistance to LH.
Massry et al [111 observed an increase of testosterone levels
in some uremic patients treated with 1 ,25(OH)2 vitamin D3, and
similar findings were reported by Blumberg et al [301. Massry et
at 1111 ascribed this observation to suppression of secondary
hyperparathyroidism. In this study, diminished ovarian cAMP
response to LH was observed both in parathyroid-intact and in
parathyroidectomized uremic rats. This finding argues against a
role of secondary hyperparathyroidism in the genesis of gonadal
resistance. Furthermore, addition of PTH to ovaries in vitro did
not raise basal cAMP levels, an observation which argues
against, but does not definitely exclude, the presence of ovarian
PTH-sensitive adenylate cyclase. Finally, in vivo administra-
tion of 1,34 PTH to control rats and addition of 1,34 PTH to
ovaries incubated in vitro, failed to affect the cAMP response to
LH.
The clinical observation of a beneficial effect of 1 ,25(OH)2
vitamin D3 on sexual hormone concentration in man would also
be compatible with a direct effect of l,25(OH)2 vitamin D3 on
the gonads. Indeed, administration of physiological doses of
l,25(OH)2 vitamin D3 to uremic animals, but not to control
animals, normalized the ovarian cAMP response to LH. This
observation suggests that absent renal l,25(OH)2 vitamin D1
synthesis in uremic animals plays a role in the gonadal resist-
ance to LH. A pharmacological action of I ,25(OH)., vitamin D3
in uremic animals seems unlikely since similar doses of
l,25(OH)2 vitamin D3 had no effect in normal animals.
The effect of 1,25(OH)2 vitamin D3 presumably was not
mediated by a rise in plasma calcium, indeed, hypercalcemia in
control animals, and addition of calcium to the incubation
medium, diminished ovarian cAMP concentration, both basal
and stimulated, presumably as a result of the known action of
calcium on adenylate cyclase activity [31]. l,25(OH)2 vitamin
D3 may have effects on intracellular calcium or calmodulin; this
possibility was not examined in the present study. A direct
action of 1 ,25(OH)7D3 by interaction with specific receptors on
ovarian membranes is suggested by the recent finding in this
laboratory of specific 1 ,25(OH)2D3 receptors on ovarian mem-
branes (Merke, Kreusser, and Ritz, in preparation) and by
demonstration of an action of 1 ,25(OH)2D3 on LH stimulated
ovarian cAMP in vitro [32].
Prostaglandins have been shown to play a major role in
modulating ovarian [33, 34] and genital [35] function in females.
Because of the known abnormalities of prostaglandin metabo-
lism in renal insufficiency [9, 101, a possible interaction of
prostaglandins and LH response was examined. It has been
shown previously in non-uremic animals that PGE2 stimulated
cAMP formation of juvenile rat ovaries in vitro [361. In this
study, PGE1 and PGE2 also increased basal and stimulated
cAMP concentration. Furthermore, a difference between the
ovaries of control rats and uremic rats was no longer demon-
strable in the presence of PGE1 or PGE2. However, prostaglan-
din levels were not measured in vivo, and it is unknown
whether ovarian prostaglandin metabolism is disturbed in ex-
perimental renal failure. In other tissues, abnormal prostaglan-
din metabolism has been demonstrated clearly 191. The possibil-
ity of abnormal ovarian prostaglandin metabolism is strength-
ened, however, by the finding that indomethacin further
diminished the LH stimulated cAMP concentration in ovaries
of uremic rats but not of control rats. No effect of indomethacin
on LH-stimulated cAMP accumulation in non-uremic animals
was also observed by Zor et al [361.
Prolactin levels were elevated in our acutely uremic rats and
such hyperprolactinemia was abolished by administration of
bromocriptine. Despite normalization of prolactin levels, the
inadequate ovarian cAMP response to LH persisted. These
findings argue against a major role of hyperprolactinemia in the
genesis of ovarian resistance to LH in acute renal failure. It is of
note that ovaries of cows possess a dopamine receptor (Profes-
sor Del Pozo, Basel, Switzerland, personal communication): it
is unlikely that this vitiates the conclusion of the bromocriptine
experiment, since basal ovarian cAMP levels remained un-
changed with the dose of bromocriptine used.
In conclusion, this study shows impaired LH-stimulated
cAMP generation in ovaries, and a diminished increment of
plasma estradiol concentration after administration of LH, in
acutely and chronically uremic rats. This finding points to
gonadal resistance to gonadotropin and might explain hyper-
gonadotropic hypogonadism in uremic patients. Furthermore,
the study shows that abnormal vitamin D and prostaglandin
metabolism play a role in the genesis of this abnormality.
Note added in proof
Ovarian l,25(OH)7D3 receptors have also been recently dem-
onstrated by other investigators (DOKAH S. DONALDSON CA,
MARION SL, PIKE JW, HAUSSLER MR: The ovary: New target
organ for l,25-dihydroxy Vitamin—D (abstract), in Proc 5th In!
Workshop on Vitamin D, Williamsburg, Virginia, Feb 14th—
19th, 1982, p. a44).
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